Abstract 1436P
Background
To understand if there is sex disparity in survival outcomes among the patients with advanced gastric adenocarcinoma (GAC), gastroesophageal junction adenocarcinoma (GEJAC), and esophageal adenocarcinoma (EAC).
Methods
The study included patients from Kaiser Permanente Northern California with metastatic or relapsed EAC, GEJAC and GAC whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of male and female patients with overall survival (OS) adjusting for demographics, performance status, Charlson comorbidity index, receipt of chemotherapy, and six most common genomic alterations including HER2 overexpression/amplification, p53, KRAS, CDKN2A, PIK3CA co-mutation and Myc amplification.
Results
Among 875 eligible patients, 275 were female and 600 were male. OS for male versus female patients did not appear substantially different for the entire cohort (HR = 0.87; [95% CI, 0.74-1.03]), for EAC (HR = 1.0; [95% CI, 0.57-1.74]) and GEJAC (HR = 1.14; (95% CI, 0.77-1.67]) subgroups. However, OS of male versus female patients with GAC appeared substantially better (HR = 0.75; [95% CI, 0.60-0.93]). In addition, this substantial OS difference was preserved regardless of HER2 status, CDKN2A and PIK3CA mutation or Myc amplification. Intriguingly, despite overall there was no OS difference between male versus female GAC patients regardless of p53 mutation status, however, among GAC patients with a p53 mutation, male had substantially better OS than female patients only if tumor carried non-gain-of-function (non-GOF, HR = 0.59; [95% CI, 0.41-0.85]) but not gain-of-function mutation (GOF, HR = 1.46; [95% CI, 0.74-2.87]).
Conclusions
We have found that male versus female GAC patients had substantially better overall survival. Most intriguingly, the survival difference among patients with mutp53 was only observed if tumor carried mutp53 non-GOF. Our results for the first time identified a sex disparity in survival outcomes that is associated with a common molecular lesion and can have important implications in understanding the biology of GAC and in clinical practice for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18
1936P - Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Presenter: José Miguel Rodellar
Session: Poster session 18